Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY

Autor: Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

Publikováno v: Mediterranean Journal of Hematology and Infectious Diseases, Vol 13, Iss 1 (2021)

Introduction: CAR-T cell therapy is likely to be introduced starting from 2021 in patients with relapsed/refractory myeloma (r/r MM) in Europe. In order to qualify for commercial CAR-T treatment, it is assumed that r/r MM patients will have to be exp

Externí odkaz: https://doaj.org/article/cdcece23a7494e8699647fa199f60c62

Significance, Challenges, and Prospects of Short-Term Online Study Abroad：\nAiming to build a more effective 'Baryu'(a concept of Value + Ryugaku)

Autor: Chiharu, NAKAYA

Publikováno v: 和洋女子大学英文学会誌 = Language and Literature of Wayo Women's University. 57:77-95

コロナ禍における「オンライン留学」は、渡航を伴う留学と同様に学生に、グローバル人材として必要な素養（主体性、異文化理解力、新たな価値観など）の醸成を与えるチャンスとな�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::31fcc2e39cbc0b396785d42331f2967f
http://id.nii.ac.jp/1159/00002076/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY

Autor: Brechbühl, Simon, Bacher, Ulrike, Jeker, Barbara, Pabst, Thomas

Publikováno v: Mediterranean Journal of Hematology and Infectious Diseases, Vol 13, Iss 1 (2021)
Mediterranean Journal of Hematology and Infectious Diseases
Brechbühl, Simon; Bacher, Ulrike; Jeker, Barbara; Pabst, Thomas (2021). Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy. Mediterranean journal of hematology and infectious diseases, 13(1), e2021012. Università Cattolica del Sacro Cuore 10.4084/MJHID.2021.012

Background CAR-T cell therapy is likely to be introduced starting from 2021 in patients with relapsed/refractory myeloma (r/r MM) in Europe. In order to qualify for commercial CAR-T treatment, it is assumed that r/r MM patients will have to be expose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bbdb07a3c40ae59fc37846980d16c1
http://www.mjhid.org/index.php/mjhid/article/view/4425